Bath‐PUVA still represents a valuable treatment option for the subsets of psoriatic patients who are not eligible to or rejecting systemic treatments and are not responsive to NB‐UVB phototherapy.

Background: Photochemotherapy with bathwater delivery of psoralens plus UVA exposures (bath‐PUVA) is mainly used for those psoriatic patients who are not responsive to narrowband (NB)‐UVB phototherapy and oral‐PUVA therapy and belong to two categories (1) patients with psoriasis without systemic comorbidities who do not need long‐term continuous treatment and (2) patients who have contraindications to immunosuppressive drugs and oral‐PUVA or refuse systemic drugs, including oral ingestion of psoralens, for personal reasons. However, it is not known how many patients belong to the second group and how much bath‐PUVA is effective and safe for them. Methods: We have reviewed the treatment results of a cohort of 120 patients with clinical indication to bath‐PUVA for the above‐mentioned reasons between 2010 and 2019. These patients were selected among 2640 patients with moderate and severe psoriasis who were treated in our department in the same time interval. Results: Ninety‐six patients completed at least one treatment cycle with bath‐PUVA. A per‐protocol analysis showed that average number of treatment sessions was 21.3 ± 9.0 and the cumulative UVA dose was 80.4 ± 60.0 J/cm2. The average PASI scores decreased from 20.8 ± 7.9 to 5.1 ± 5.4 (p <.01). Sixty‐seven (69.7%) patients achieved at least a 75% improvement (PASI75) and, of them, 38 (39.6%) had an improvement greater than 90% (PASI90). Adverse effects were mild and transitory. Conclusion: These findings demonstrate that bath‐PUVA is still a valuable treatment option for a high number of patients who reject systemic treatments or have contraindications to systemic immune‐modifying drugs and have had a limited or no improvement with NB‐UVB phototherapy. [ABSTRACT FROM AUTHOR]